EBV Treatment with Zephyr® Valves

Managing exacerbations can meaningfully reduce symptoms and future risk in patients with severe COPD/emphysema. A single-center, multi-year, retrospective study reveals a 32% decrease in the rate of moderate and severe exacerbations for severe COPD/emphysema patients one year after Endobronchial Valve (EBV) Treatment.1

Read study summary https://pulmonx.com/clinical-evidence/#recent-clinical-data

Among the EBV treatment options, Zephyr® Valves are backed by extensive clinical evidence, with multiple randomized controlled trials (RCTs) demonstrating their effectiveness in improving lung function, exercise capacity, and quality of life.2-5

Patient Eligibility
Patients who meet the following criteria may benefit from the Zephyr Valve treatment:

• Severe COPD/emphysema with evidence of hyperinflation.
• Persistent breathlessness (mMRC ≥ 2) despite optimal medical management.
• Dissatisfied with current activity level and quality of life
• FEV1 < 50%.

By identifying eligible patients early, physicians can help reduce exacerbations and provide life-changing improvements in their health status.

Learn more on patient selection and eligibility criteria: Pulmonx Patient Selection Page.

Important safety information: https://pulmonx.com/prescriptive-information/

References:

1.     Brock et al, Respir Med. 2023; 218:107399. doi: 10.1016/j.rmed.2023.107399.
2.     Criner, G et al. Am J Resp Crit Care Med. 2018 Nov 1;198(9):1151-1164.
3.     Kemp, SV et al. Am J Respir Crit Care Med. 2017 Dec 15;196(12):1535-1543.
4.     Valipour, A et al. Am J Respir Crit Care Med, 2016 Nov 1;194(9):1073-1082 and data on file at Pulmonx.
5.     Klooster, K et al. N Engl J Med. 2015 Dec 10;373(24):2325-2335.